(Q87395602)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022399%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

A simple approach for enhanced immune response using engineered dendritic cell targeted nanoparticles (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022399%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

0 references

1 reference

Dharmendra Raghuwanshi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022399%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Vivek Mishra

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022399%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Mavanur R Suresh

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022399%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Kamaljit Kaur

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022399%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

publication date

26 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022399%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022399%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022399%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022399%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

7292-7299

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022399%20AND%20SRC:MED&resulttype=core&format=json

Dendritic cells and the control of immunity

9 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Improving vaccines by targeting antigens to dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

'Dressed for success' C-type lectin receptors for the delivery of glyco-vaccines to dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

C-type lectin receptors on dendritic cells and Langerhans cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

In Vivo Targeting of DC-SIGN-positive Antigen-presenting Cells in a Nonhuman Primate Model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Cutting edge: langerin/CD207 receptor on dendritic cells mediates efficient antigen presentation on MHC I and II products in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Antigenic targeting of the human mannose receptor induces tumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. I. Expression on dendritic cells and other subsets of mouse leukocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC-205/CD205-positive mouse dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti–human DEC205 monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Exploiting lymphatic transport and complement activation in nanoparticle vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Development of synthetic biodegradable microparticulate vaccines: a roller coaster story.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Particulate vaccines: on the quest for optimal delivery and immune response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Enhancement of immune response of HBsAg loaded poly (L-lactic acid) microspheres against hepatitis B through incorporation of alum and chitosan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

A versatile bifunctional dendritic cell targeting vaccine vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

In vitro macrophage uptake and in vivo biodistribution of long-circulation nanoparticles with poly(ethylene-glycol)-modified PLA (BAB type) triblock copolymer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Characterization of rhodamine loaded PEG-g-PLA nanoparticles (NPs): effect of poly(ethylene glycol) grafting density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Coupling of biotin-(poly(ethylene glycol))amine to poly(D,L-lactide-co-glycolide) nanoparticles for versatile surface modification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Stimulation of dendritic cells via CD40 enhances immune responses to Mycobacterium tuberculosis infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

The two faces of IL-6 on Th1/Th2 differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

The impact of nanoparticle ligand density on dendritic-cell targeted vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Regulatory conversation between antigen presenting cells and regulatory T cells enhance immune suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

Programming the magnitude and persistence of antibody responses with innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.036

10.1016/J.VACCINE.2012.09.036

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022399%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference